Weight Loss in People Living With Overweight or Obesity Following Treatment With Cagrilintide

Inclusion criteria:

• Informed consent obtained before any study-related activities. Study-relatedactivities are any procedures that are carried out as part of the study, includingactivities to determine suitability for the study

• Female or male (sex at birth)

• Age 18 years or above at the time of signing the informed consent

• History of at least one self-reported unsuccessful dietary effort to lose bodyweight (a*)

• Body mass index (BMI) greater than or equal to >= 30.0 kilogram per square meter (kg/m^2), or BMI greater than or equal to >= 27.0 kg/m^2 with the presence of atleast one weight related comorbidity including, but not limited to, hypertension,dyslipidaemia, obstructive sleep apnoea or cardiovascular disease (a*)

Exclusion criteria:

• History of type 1 or type 2 diabetes (a*)

• Treatment, or intention to initiate treatment, with any medication prescribed forthe indication of weight management within 180 days before screening (a*)

• Previous dosing of marketed or non-marketed amylin-based compounds (a*) (a*) - Asdeclared by the participant, reported in the medical records or at theinvestigator's discretion.